Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections

Gene Therapy volume 12, pages 1494–1502 (2005)Cite this article

Abstract

Host defense peptides (HDP) are naturally occurring effector molecules of the innate immune system, which might be an alternative to currently used antibiotics. The objective of this study was to investigate the efficiency of transient cutaneous adenoviral transfection with human cathelicidin hCAP-18/LL-37 in infected burn wounds. Specific transgene expression was analyzed in vitro on mRNA and protein level using real-time PCR and Western-blot. Male Sprague–Dawley rats (n=40) received a second degree scald burn on both flanks (5% BSA), which were inoculated with 108 colony-forming units (CFU) Pseudomonas aeruginosa. Two days later, rats were randomized into the following groups: (1) adenoviral delivery of LL-37 (Ad5-hCAP-18, n=10), (2) synthetic host defense peptide LL-37 (1 mg; n=10), (3) carrier control (PBS, n=10) and (4) empty-virus control (Ad5-LacZ, n=10). Agents were injected intradermally and subcutaneously into both flanks. After either 2 or 7 days, skin samples were harvested and homogenized. CFU per gram tissue were determined. The hCAP-18/LL-37 expression was confirmed by real-time PCR and localized using in situ hybridization. In vitro transfection of cutaneous cells delivered a specific response on mRNA production. Western blot analysis revealed protein expression of hCAP-18/LL-37 in conditioned medium and cell pellet. The host defense peptide LL-37 was detectable after cleavage of the inactive pro-form hCAP-18/LL-37 with human elastase. Ad5-hCAP-18 showed a significant bacterial inhibition of approximately 10 000 fold compared to the control group (P<0.001) and 1000-fold (P<0.001) compared to the synthetic HDP LL-37 7 post-transfection. No inhibition was observed for the carrier or empty-virus control. Real-time PCR and in situ hybridization confirmed expression of hCAP-18/LL-37. In conclusion, transient cutaneous adenoviral delivery of the host defense peptide hCAP-18/LL-37 is significantly more effective than administration of synthetic host defense peptides and might be a potential adjunct for wound treatment in the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Pruitt Jr BA, McManus AT, Kim SH, Goodwin CW . Burn wound infections: current status. World J Surg 1998; 22: 135–145.

    Article  PubMed  Google Scholar 

  2. Estahbanati HK, Kashani PP, Ghanaatpisheh F . Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns 2002; 28: 340–348.

    Article  PubMed  Google Scholar 

  3. Alekseev AA, Iakovlev VP, Fedorov VD . Infection in burn patients: the problems of pathogenesis, prevention and treatment. Khirurgiia (Mosk) 1999; 6: 4–9.

    Google Scholar 

  4. Lindberg RB et al. The successful control of burn wound sepsis. J Trauma 1965; 5: 601–616.

    Article  CAS  PubMed  Google Scholar 

  5. Stone HH . Review of Pseudomonas sepsis in thermal burns: verdoglobin determination and gentamicin therapy. Ann Surg 1966; 163: 297–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fox Jr CL, Rappole BW, Stanford W . Control of Pseudomonas infection in burns by silver sulfadiazine. Surg Gynecol Obstet 1969; 128: 1021–1026.

    PubMed  Google Scholar 

  7. Hanberger H et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281: 67–71.

    Article  CAS  PubMed  Google Scholar 

  8. Lehrer RI, Ganz T . Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 1999; 11: 23–27.

    Article  CAS  PubMed  Google Scholar 

  9. Zanetti M, Gennaro R, Romeo D . Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374: 1–5.

    Article  CAS  PubMed  Google Scholar 

  10. Bals R, Wang X, Zasloff M, Wilson JM . The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95: 9541–9546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Frohm M et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272: 15258–15263.

    Article  CAS  PubMed  Google Scholar 

  12. Ganz T, Weiss J . Antimicrobial peptides of phagocytes and epithelia. Semin Hematol 1997; 34: 343–354.

    CAS  PubMed  Google Scholar 

  13. Frohm M et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 1996; 237: 86–92.

    Article  CAS  PubMed  Google Scholar 

  14. Bals R . Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000; 1: 141–150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Koczulla R et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665–1672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lawrence JC . Burn bacteriology during the last 50 years. Burns 1992; 18 (Suppl 2): S23–S29.

    Article  PubMed  Google Scholar 

  17. Milner SM, Ortega MR . Reduced antimicrobial peptide expression in human burn wounds. Burns 1999; 25: 411–413.

    Article  CAS  PubMed  Google Scholar 

  18. Ortega MR, Ganz T, Milner SM . Human beta defensin is absent in burn blister fluid. Burns 2000; 26: 724–726.

    Article  CAS  PubMed  Google Scholar 

  19. Almeida MS et al. Solution structure of Pisum sativum defensin 1 by high resolution NMR: plant defensins, identical backbone with different mechanisms of action. J Mol Biol 2002; 315: 749–757.

    Article  CAS  PubMed  Google Scholar 

  20. Campain JA et al. Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines. Cancer Gene Ther 1998; 5: 131–143.

    CAS  PubMed  Google Scholar 

  21. Campbell C et al. Green fluorescent protein-adenoviral construct as a model for transient gene therapy for human cultured keratinocytes in an athymic mouse model. J Trauma 2003; 54: 72–79; discussion 79–80.

    Article  CAS  PubMed  Google Scholar 

  22. Domashenko A, Gupta S, Cotsarelis G . Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol 2000; 18: 420–423.

    Article  CAS  PubMed  Google Scholar 

  23. Benn SI et al. Particle-mediated gene transfer with transforming growth factor-beta1 cDNAs enhances wound repair in rat skin. J Clin Invest 1996; 98: 2894–2902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Davidson JM et al. Gene therapy of wounds with growth factors. Curr Top Pathol 1999; 93: 111–121.

    Article  CAS  PubMed  Google Scholar 

  25. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215–222.

    Article  CAS  PubMed  Google Scholar 

  26. Steinstraesser L et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46: 1837–1844.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Nizet V et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454–457.

    Article  CAS  PubMed  Google Scholar 

  28. Steinstraesser L, Oezdogan Y, Wang SC, Steinau HU . Host defense peptides in burns. Burns 2004; 30: 619–627.

    Article  CAS  PubMed  Google Scholar 

  29. Chung WO, Dale BA . Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun 2004; 72: 352–358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sorensen OE et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951–3959.

    Article  CAS  PubMed  Google Scholar 

  31. Cole AM et al. Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood 2001; 97: 297–304.

    Article  CAS  PubMed  Google Scholar 

  32. Zasloff M . Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389–395.

    Article  CAS  PubMed  Google Scholar 

  33. Agerberth B et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086–3093.

    CAS  PubMed  Google Scholar 

  34. Nagaoka I et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 2002; 9: 972–982.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Hancock RE . Peptide antibiotics. Lancet 1997; 349: 418–422.

    Article  CAS  PubMed  Google Scholar 

  36. Shafer WM, Qu X, Waring AJ, Lehrer RI . Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998; 95: 1829–1833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Breithaupt H . The new antibiotics. Nat Biotechnol 1999; 17: 1165–1169.

    Article  CAS  PubMed  Google Scholar 

  38. Latham PW . Therapeutic peptides revisited. Nat Biotechnol 1999; 17: 755–757.

    Article  CAS  PubMed  Google Scholar 

  39. Sylvester KG et al. Adenoviral-mediated gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen 2000; 8: 36–44.

    Article  CAS  PubMed  Google Scholar 

  40. Schiff GD et al. Improving inpatient antibiotic prescribing: insights from participation in a national collaborative. Jt Comm J Qual Improv 2001; 27: 387–402.

    CAS  PubMed  Google Scholar 

  41. Bals R et al. Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun 1999; 67: 3542–3547.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Christensen R, Jensen UB, Jensen TG . Cutaneous gene therapy—an update. Histochem Cell Biol 2001; 115: 73–82.

    Article  CAS  PubMed  Google Scholar 

  43. Koczulla AR, Bals R . Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389–406.

    Article  CAS  PubMed  Google Scholar 

  44. Blau HM, Springer ML . Gene therapy—a novel form of drug delivery. N Engl J Med 1995; 333: 1204–1207.

    Article  CAS  PubMed  Google Scholar 

  45. Leiden JM . Gene therapy—promise, pitfalls, and prognosis. N Engl J Med 1995; 333: 871–873.

    Article  CAS  PubMed  Google Scholar 

  46. Grayson LS et al. Quantitation of cytokine levels in skin graft donor site wound fluid. Burns 1993; 19: 401–405.

    Article  CAS  PubMed  Google Scholar 

  47. Harvey BG et al. Cellular immune responses of healthy individuals to intradermal administration of an E1–E3-adenovirus gene transfer vector. Hum Gene Ther 1999; 10: 2823–2837.

    Article  CAS  PubMed  Google Scholar 

  48. St George JA . Gene therapy progress and prospects: adenoviral vectors. Gene Therapy 2003; 10: 1135–1141.

    Article  CAS  PubMed  Google Scholar 

  49. Somia N, Verma IM . Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91–99.

    Article  CAS  PubMed  Google Scholar 

  50. Heilborn JD et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379–389.

    Article  CAS  PubMed  Google Scholar 

  51. Yang Y, Li Q, Ertl HC, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Goosney DL, Nemerow GR . Adenovirus infection: taking the back roads to viral entry. Curr Biol 2003; 13: R99–R100.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We sincerely thank Janine Mertens and Sabine Böhm for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, Ste1099).

Author information

Authors and Affiliations

  1. Plastic Surgery Research Department for Plastic Surgery, Burn Center, Handsurgery, Sarcoma Reference Center, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany

    F Jacobsen, D Mittler, T Hirsch, A Gerhards, M Lehnhardt, H U Steinau & L Steinstraesser

  2. Berufsgenossenschaftliches Forschungsinstitut für Arbeitsmedizin (BGFA), Ruhr-University Bochum, Bochum, Germany

    B Voss

Authors
  1. F Jacobsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Mittler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Gerhards
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Lehnhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H U Steinau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Steinstraesser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobsen, F., Mittler, D., Hirsch, T. et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 12, 1494–1502 (2005). https://doi.org/10.1038/sj.gt.3302568

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302568

Keywords

This article is cited by

Search

Advanced search

Quick links